- Company
- Suganon by Dong-A ST, approved for Phase II/III in the US
- by An, Kyung-Jin Sep 24, 2020 06:19am
- Dong-A ST announced on the 22nd that the diabetes treatment 'Suganon' (Evogliptin) has been approved by the US Food and Drug Administration (FDA) for Phase IIb/IIIa clinical trial plan (IND) for aortic heart valve calcification. Suganon is a diabetes treatment based on DPP-4 inhibitor developed by Dong-A ST. In order to use Suganon other
- Policy
- Certican keeps weighted pricing for now, Samsca lowered 30%
- by Kim, Jung-Ju Sep 24, 2020 06:19am
- Novartis Korea’s immunosuppressant Certican (everolimus) has ultimately dodged the double pricing reduction. Although dismissed from patent litigation and lost from the administrative litigation against the government, the immunosuppressant is to keep its premium pricing benefit as stipulated by the policy that sustains the benefit when the num
- Company
- Suganon, a new domestic drug that is evolving
- by An, Kyung-Jin Sep 23, 2020 08:06pm
- Suganon (Evogliptin), a diabetes treatment developed by Dong-A ST's proprietary technology, has stepped up its competitiveness. Despite the return of rights, efforts are being made to improve the value of new drugs while seeking new indications. The growth of domestic sales has gained momentum, and it is advancing into overseas markets by co
- Product
- Pharmacies rage on non-refundable price-reduced drug
- by Jung, Heung-Jun Sep 23, 2020 06:21am
- The pricings of four doses of Novartis’ immunosuppressant Certican have been brought down by 30 percent as of Sept. 20, and pharmacies are outraged with the pharmaceutical company refusing to refund the single tablets. Pharmacists are questioning the company’s refund policy as it would solely burden the pharmacies with the differences m
- Policy
- Italian-made Gliatirin and Vesseldue-F efficacy questioned
- by Lee, Tak-Sun Sep 23, 2020 06:21am
- A series of drugs from Italian manufacturers are in a tight spot, as they have been selected as an efficacy reevaluation subjects. These drugs do not have sufficient evidence to prove the efficacy, because they hardly have much records of use in countries other than South Korea. The pharmaceutical industry sources reported on Sept. 20, S
- Company
- Samsung signed manufacturing collaboration with AZ
- by Eo, Yun-Ho Sep 22, 2020 05:47pm
- AstraZeneca and Samsung Biologics announced the signing of a long-term supply agreement. Under this agreement, valued at approximately $330.8 million, Samsung Biologics will provide large-scale commercial manufacturing for drug substance and drug product of AstraZeneca biologics therapeutics. The contract value could grow to $545.6 millio
- Company
- Cyramza+Tarceva shoots for first-line in EGFR NSCLC patients
- by Eo, Yun-Ho Sep 22, 2020 06:27am
- A combined targeted therapy is seeking for healthcare reimbursement as a first-line treatment in patients with non-small cell lung cancer (NSCLC). The pharmaceutical industry source reported Lilly Korea has recently submitted an application to expand reimbursement on a vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyra
- Policy
- Generic companies for Atozet are interested in contractors
- by Lee, Tak-Sun Sep 22, 2020 06:27am
- It is known that generic companies of the hyperlipidemia complex Atozet(Atorvastatin-Ezetimibe, Chong Kun Dang) will sign a consignment contract with Chong Kun Dang today (22nd). Generic companies are paying attention to the number of final contractors and scrutinizing their strengths and weaknesses. According to the industry on the 21st
- Policy
- ORR 100%, Phase III of Lazertinib combination was approved
- by Lee, Tak-Sun Sep 22, 2020 06:26am
- The clinical trial of Lazertinib-Amivantamab, which was released by Janssen at the European Society for Medical Oncology (ESMO) on the 20th, is also being conducted in Korea. As a result of this interim study, the response rate (ORR) was 100%, raising expectations as a treatment for non-small cell lung cancer that threatens Tagrisso. Laz
- Company
- Ho-jin Choi inaugurated as CEO of Ono Pharma Korea
- by An, Kyung-Jin Sep 22, 2020 06:26am
- Ono Pharma Korea said that it has elected Choi Ho-jin, vice president of Ono Pharma Korea, as its new chief executive officer effective on Oct. 1. Ono Pharma Korea was established in December 2013 as a Korean subsidiary of Ono Pharmaceutical Co., Ltd. in Japan. New CEO Choi has contributed significantly to the local launch and reimbursemen
